Clinical Trials Logo

Respiratory Tract Diseases clinical trials

View clinical trials related to Respiratory Tract Diseases.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05745467 Withdrawn - Clinical trials for SARS-CoV-2 Acute Respiratory Disease

Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2

Start date: July 3, 2024
Phase: Phase 4
Study type: Interventional

The primary aim is to test whether preoperative asepsis with 5% nasal povidone iodine versus no preoperative asepsis with 5% nasal povidone iodine reduces proximal and distal SARS-CoV-2 transmission in operating rooms among patients who are acutely infected with SARS-CoV-2. The secondary aim is to test viral infectivity.

NCT ID: NCT05661422 Withdrawn - Asthma Clinical Trials

Analysis of Lung Sounds Collected by RESP Biosensor to Support Decision Making in Monitored Hospitalized Pediatric Patients

Start date: March 2023
Phase:
Study type: Observational

This observational clinical trial is designed to confirm whether RESP™ Biosensor could be deployed to support clinical decision making in challenging pediatric cases, minimize clinician-to-clinician variability in lung sound interpretation, obviate the need to disrupt change of shift or chart rounds with physicians, and create a durable archive of the patient's lung sounds for longitudinal comparison within or across hospitalizations.

NCT ID: NCT05085574 Withdrawn - COVID-19 Clinical Trials

Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

Start date: February 7, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19 (based on World Health Organization [WHO] Ordinal Scale for Clinical Improvement). Both famotidine and celecoxib separately demonstrate clinical activity in mitigating COVID-19 disease symptoms or severity, and appear to have separate and complementary mechanisms of action.

NCT ID: NCT04913142 Withdrawn - Clinical trials for SARS-CoV-2 Acute Respiratory Disease

About Oral and Gut Microbiota in Intensive Care Unit : SARS-CoV-2 (COVID-19) Infection Impact.

CO-MIC
Start date: June 15, 2021
Phase:
Study type: Observational

The objective of the present study is to describe the negative impact on oral and gut microbiota of a severe acute respiratory syndrome SARS-CoV-2 infection in patients hospitalized in intensive care units (ICU). The study would like to compare their microbiota to the microbiota of ICU patients, non-infected by the SARS-CoV-2.

NCT ID: NCT04894682 Withdrawn - Lung Cancer Clinical Trials

Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor

CoVac-Lung
Start date: May 4, 2021
Phase:
Study type: Observational

The objective of this study is to assess the inoculation-related symptoms and long-term effects of COVID-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting. The investigators aim to provide high-quality evidence for the COVID-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.

NCT ID: NCT04842331 Withdrawn - Clinical trials for COVID-19 Respiratory Infection

PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)

PREVENT
Start date: September 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is an open label controlled household-randomised trial designed to evaluate the efficacy of RESP301 alongside standard of care ("SOC") versus SOC alone.

NCT ID: NCT04456088 Withdrawn - COVID-19 Clinical Trials

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)

Start date: July 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

NCT ID: NCT04361669 Withdrawn - Cancer Clinical Trials

Hospice Quality Score Assessment Post Pharmacist Intervention

Start date: April 22, 2020
Phase:
Study type: Observational

The study aims to investigate the impact of pharmacist delivered interventions on hospice patients quality metric scores.

NCT ID: NCT04341610 Withdrawn - Clinical trials for Respiratory Tract Diseases

ASC Therapy for Patients With Severe Respiratory COVID-19

ASC COVID-19
Start date: April 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The emerging field of stem cell therapy holds promise of treating a variety of diseases. Especially the mesenchymal stromal cells from bone marrow or adipose tissue (ASCs) have proven their potential for regenerative therapy in patients with ischemic heart disease. Both of these cell types have putative immunomodulatory properties, as they have demonstrated their ability to evade recognition and actively suppress the immune system. This knowledge is transferred into studies with COVID-19 patients having severe pulmonary dysfunction, to modify the virus induced immunological and inflammatory activity involved in the progression of disease often leading to prolonged ICU stay and in some occasion's death. We will conduct a clinical trial in which patients with COVID-19 and severe pulmonary symptoms will be randomized to either placebo or treatment with allogeneic CSCC_ASCs from adipose tissue. The aim is to assess the impact of CSCC_ASCs on the activated immune system and clinical efficacy on pulmonary function. The perspective is that this new information can be of pivotal importance and potentially be a paradigm shift for the clinical problems and severe outcome seen in some patients with severe COVID-19 and other severe diseases with Acute Respiratory Distress Syndrome.

NCT ID: NCT03428737 Withdrawn - Clinical trials for Noctural Ventilatory Mode and Weaning Duration

Impact of a Nocturnal Pressure Controlled Ventilation on Mechanical Ventilation Weaning Duration in Patients With Chronic Obstructive Respiratory Diseases

REVENTIL 2
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The weaning of mechanical ventilation is difficult period. This period is particularly difficult for patient with obstructive chronic respiratory disease and a long mechanical ventilation is associated with an increased risk of infectious complication, cardiac dysfunction, muscular weakness or barotromatism. No guideline is available on the ventilator mode to use during the night. In weaning period, some studies have demonstrated that nocturnal control ventilation during the weaning period improved the quality and the quantity of sleep. The hypothesis is that use of nocturnal controlled mechanical ventilation could decrease the weaning period duration and the ventilation weaning failure because of a sleep improvement. The main objective is to compare mechanical ventilation weaning period duration according to the nocturnal ventilator mode (pressure controlled ventilation versus pressure support ventilation) in patients with an obstructive respiratory disease. A secondary objective is to evaluate the rate of weaning failure after the first extubation according to the nocturnal ventilator mode and to evaluate the sleep during the weaning period according to the nocturnal ventilator mode.